Navigation Links
Mylan Announces Transition of Chief Financial Officer

PITTSBURGH, Feb. 19 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its Chief Financial Officer, Edward J. Borkowski, will transition out of his role over the next several months. Borkowski will remain with Mylan until a successor is named and in place.

Mylan's Vice Chairman and CEO Robert J. Coury stated: "Not only do I want to thank Ed for the commitment he brought to Mylan over the last seven years, I want to commend him for the role he played in supporting me and Mylan during the company's transformation, especially in helping to build a very strong foundation for the company to grow and in establishing a sound and balanced capital structure. It is with both optimism and gratitude that we make this announcement today, and I am pleased that Ed will continue to direct our finance team through this transition while a new CFO is successfully recruited and on board over the next few months."

Borkowski stated: "Since I began my tenure at Mylan seven years ago, I've had the absolute pleasure to work with Robert Coury and the Mylan management team in executing the company's vision and growth strategy, which has resulted in Mylan's transformation from a U.S.-based generic drug company to a leading global provider of quality generic and specialty pharmaceuticals. We have achieved a great deal over the last several years, and I'm very proud that I've been able to complete all that was asked of me. As Mylan has entered into the next phase of executing on its global operational goals, I believe that it is an appropriate time for me to be able to move on to new challenges. Mylan is well positioned to succeed on the global stage, and I am proud to have been a part of Mylan's continued growth and leadership in the industry."

Mylan has retained the executive recruitment firm Korn/Ferry International to lead the search for Borkowski's replacement.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Mylan Announces Final FDA Approval for Carvedilol Tablets
3. Mylan Announces Tentative FDA Approval for Topiramate Capsules
4. Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance Officer
5. Mylan Announces Extension of Tender Offers for Its 5.750% Senior Notes due 2010 and 6.375% Senior Notes due 2015
6. Mylan Announces Appointment of David A. Lillback as Senior Vice President and Global Head of Human Resources
7. Mylan Announces Appointment of Brian Byala as Senior Vice President and Treasurer
8. Mylan Announces Appointment of Didier Barret as President, Europe, Middle East and Africa
9. Mylan Announces Appointment of Harry A. Korman as President, North America
10. Mylan Announces Appointment of John Montgomery as President, Asia Pacific
11. Mylan Announces Management of Specialty Business, Dey L.P.
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... It takes only three to five ... is critical that the first impression be positive and reflects business values. If a ... buy anything or want to return. They will also share their thoughts about a ...
(Date:11/24/2015)... PLAINSBORO, N.J. (PRWEB) , ... November 24, 2015 ... ... experts will gather to share their knowledge and experiences at a live taping ... during the Ruesch Center for the Cure of Gastrointestinal Cancers 2015 Symposium at ...
(Date:11/24/2015)... ... 24, 2015 , ... Aided by seed funding from the Ron Foley Foundation, ... yield insights into how to detect and treat pancreatic cancer (PC). , WCHN ... non-coding RNA molecules (ncRNA), genetic material that is present in the blood of patients ...
(Date:11/24/2015)... ... November 24, 2015 , ... Sir Grout of Baltimore ... TrustDale certification. The award recognizes good companies for excellence in service and a ... grout, and hard surface restoration company earned this recognition after a thorough review ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... of patented products, announces Innovative Blending, a household invention that revolutionizes the vending ... Juice & Smoothie Bars market is worth $2 billion," says Scott Cooper, CEO ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... YORK , Nov. 24, 2015 iRhythm Technologies, ... advancing cardiac care, today announced that it will participate in the ... Hotel in New York, NY . ... present on Tuesday December 1, 2015 at 8:50am ET. ... . --> . ...
(Date:11/24/2015)... 24, 2015 --> ... MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists ... grow at the fastest rates? This visiongain ... trends, opportunities and prospects there. ,  ,Our 199-page report ... lucrative areas in the industry and the future market ...
(Date:11/24/2015)... Inc., an industry leader in LCD screen protection and glare-elimination technology, is providing a vital solution ... patient monitoring or electronic documentation system. Photo - ... ... ... A study in 2013 by the National Institutes of ...
Breaking Medicine Technology: